NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for
The National Institute for Health and Care Excellence (NICE) process for single technology appraisals (STA) has been established for many years with clear cost effectiveness thresholds.
Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
